NO327200B1 - Kombinasjonspreparat for anvendelse ved demens og fremgangsmate for fremstilling derav. - Google Patents

Kombinasjonspreparat for anvendelse ved demens og fremgangsmate for fremstilling derav. Download PDF

Info

Publication number
NO327200B1
NO327200B1 NO19980786A NO980786A NO327200B1 NO 327200 B1 NO327200 B1 NO 327200B1 NO 19980786 A NO19980786 A NO 19980786A NO 980786 A NO980786 A NO 980786A NO 327200 B1 NO327200 B1 NO 327200B1
Authority
NO
Norway
Prior art keywords
chain
carbon atoms
branched
straight
compound
Prior art date
Application number
NO19980786A
Other languages
English (en)
Norwegian (no)
Other versions
NO980786L (no
NO980786D0 (no
Inventor
Karl Rudolphi
Hans-Peter Schubert
Hildegard Nimmesgern
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO980786D0 publication Critical patent/NO980786D0/no
Publication of NO980786L publication Critical patent/NO980786L/no
Publication of NO327200B1 publication Critical patent/NO327200B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
NO19980786A 1997-02-26 1998-02-25 Kombinasjonspreparat for anvendelse ved demens og fremgangsmate for fremstilling derav. NO327200B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19707655A DE19707655A1 (de) 1997-02-26 1997-02-26 Kombinationspräparat zur Anwendung bei Demenz

Publications (3)

Publication Number Publication Date
NO980786D0 NO980786D0 (no) 1998-02-25
NO980786L NO980786L (no) 1998-08-27
NO327200B1 true NO327200B1 (no) 2009-05-11

Family

ID=7821517

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19980786A NO327200B1 (no) 1997-02-26 1998-02-25 Kombinasjonspreparat for anvendelse ved demens og fremgangsmate for fremstilling derav.

Country Status (30)

Country Link
US (1) US6037347A (cs)
EP (1) EP0867192B1 (cs)
JP (1) JP4374440B2 (cs)
KR (1) KR100517186B1 (cs)
CN (1) CN100363005C (cs)
AR (1) AR011860A1 (cs)
AT (1) ATE295738T1 (cs)
AU (1) AU749278C (cs)
BR (1) BR9800766A (cs)
CA (1) CA2230350C (cs)
CZ (1) CZ298367B6 (cs)
DE (2) DE19707655A1 (cs)
DK (1) DK0867192T3 (cs)
EE (1) EE03387B1 (cs)
ES (1) ES2242243T3 (cs)
HR (1) HRP980097B1 (cs)
HU (1) HUP9800396A3 (cs)
ID (1) ID19941A (cs)
IL (1) IL123453A (cs)
MY (1) MY120530A (cs)
NO (1) NO327200B1 (cs)
NZ (1) NZ329839A (cs)
PL (1) PL191576B1 (cs)
PT (1) PT867192E (cs)
RU (1) RU2194508C2 (cs)
SI (1) SI0867192T1 (cs)
SK (1) SK284925B6 (cs)
TR (1) TR199800302A3 (cs)
TW (1) TW590772B (cs)
ZA (1) ZA981561B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20090023778A1 (en) * 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
RU2616247C1 (ru) * 2016-03-28 2017-04-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинский государственный университет имени Коста Левановича Хетагурова" (СОГУ) Твердая лекарственная форма, обладающая холинопозитивным действием, на основе 9-бутиламино-3,3-диметил-1,2,4-тригидроакридина

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
EP0179383B1 (en) * 1984-10-25 1991-05-29 Hoechst-Roussel Pharmaceuticals Incorporated 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
IL87861A0 (en) * 1987-10-05 1989-03-31 Pfizer 4-aminopyridine derivatives
RU2039058C1 (ru) * 1988-03-30 1995-07-09 Пфайзер Инк. Производные 4-аминопиридина
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
EP0491792A4 (en) * 1989-09-15 1992-12-02 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
RU2024509C1 (ru) * 1991-05-07 1994-12-15 Всероссийский научный центр по безопасности биологически активных веществ Производные 9-аминоакридина или их соли с органическими или неорганическими кислотами, проявляющие психотропную, антиамнестическую и липидрегулирующую активность
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment

Also Published As

Publication number Publication date
CZ298367B6 (cs) 2007-09-12
SK24098A3 (en) 1998-09-09
US6037347A (en) 2000-03-14
PL325074A1 (en) 1998-08-31
DE59812801D1 (de) 2005-06-23
CZ54098A3 (cs) 1998-09-16
TR199800302A2 (xx) 1998-09-21
BR9800766A (pt) 1999-12-07
TR199800302A3 (tr) 1998-09-21
TW590772B (en) 2004-06-11
EP0867192B1 (de) 2005-05-18
CA2230350A1 (en) 1998-08-26
SK284925B6 (sk) 2006-02-02
HU9800396D0 (en) 1998-04-28
NO980786L (no) 1998-08-27
EE9800075A (et) 1998-10-15
CN1192904A (zh) 1998-09-16
PT867192E (pt) 2005-08-31
HRP980097B1 (en) 2006-09-30
RU2194508C2 (ru) 2002-12-20
AR011860A1 (es) 2000-09-13
ZA981561B (en) 1998-08-26
MX9801515A (es) 1998-08-30
NO980786D0 (no) 1998-02-25
HRP980097A2 (en) 1998-12-31
CA2230350C (en) 2007-07-24
EP0867192A2 (de) 1998-09-30
ES2242243T3 (es) 2005-11-01
AU749278C (en) 2003-07-31
IL123453A0 (en) 1998-09-24
NZ329839A (en) 2000-05-26
EP0867192A3 (de) 2000-12-06
EE03387B1 (et) 2001-04-16
HUP9800396A3 (en) 2001-05-28
SI0867192T1 (en) 2005-10-31
JPH10236979A (ja) 1998-09-08
IL123453A (en) 2004-06-20
CN100363005C (zh) 2008-01-23
HUP9800396A1 (hu) 1999-07-28
ATE295738T1 (de) 2005-06-15
AU749278B2 (en) 2002-06-20
KR19980071717A (ko) 1998-10-26
DE19707655A1 (de) 1998-08-27
DK0867192T3 (da) 2005-09-05
JP4374440B2 (ja) 2009-12-02
KR100517186B1 (ko) 2005-12-05
MY120530A (en) 2005-11-30
PL191576B1 (pl) 2006-06-30
AU5627398A (en) 1998-09-03
ID19941A (id) 1998-08-27

Similar Documents

Publication Publication Date Title
US7935823B2 (en) Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use
Tanganelli et al. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease
NO327200B1 (no) Kombinasjonspreparat for anvendelse ved demens og fremgangsmate for fremstilling derav.
Thakkar et al. Effect of rapid eye movement sleep deprivation on rat brain monoamine oxidases
EP1666037A2 (en) Compositions for stimulating neurite growth
Zhang et al. Emerging targets and new small molecule therapies in Parkinson’s disease treatment
US11136328B2 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
EP2763676B1 (en) Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
CZ6498A3 (cs) Použití rapamycinu a jeho derivátů v kombinaci s antagonistou NMDA a/nebo AMPA pro výrobu farmaceutických prostředků
HRP960372A2 (en) (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate tridydrate
Jijón-Lorenzo et al. Presynaptic dopamine D2 receptors modulate [3H] GABA release at StriatoPallidal terminals via activation of PLC→ IP3→ calcineurin and inhibition of AC→ cAMP→ PKA signaling cascades
MacInnis et al. Spatial requirements for TrkA kinase activity in the support of neuronal survival and axon growth in rat sympathetic neurons
TW201429476A (zh) 包含阿茲海默症等神經疾患之１，２５ｄ３－ｍａｒｒｓ相關治療藥及治療法
CA2941096C (en) Phosphodiesterase-4 inhibiting compositions comprising sceletium spp. extract
KR102816541B1 (ko) 선택적 mTORC2 저해제 및 이의 용도
MXPA98001515A (en) Prepared combination for application in the demen
EP1736474A1 (en) Piperidine derivative
Lin et al. 2-Chloroadenosine decreases tyrosylprotein sulfotransferase activity in the Golgi apparatus in PC12 cells. Evidence for a novel receptor
WO2005009359A2 (en) Agents, compositions and methods for enhancing neurological function
Plesneva et al. Adenylate cyclase system of the rat striatum: regulatory properties and the effects of gangliosides
Hadjiivanova et al. P-12-1 Effect of dotarizine on K+-stimulated [3H]-serotonin and [3H]-acetylcholine release from rat hippocampus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees